- Exosomes are not cells. They are tiny vesicles that cells release to communicate — carrying growth factors, peptides and messenger RNA to other cells.
- Much of what stem cell therapy achieves may be down to the exosomes those cells release, rather than the cells themselves engrafting.
- Sourcing is the entire conversation. Product quality varies enormously between suppliers, and the FDA has taken enforcement action in this space.
- The mechanism is compelling and the human trial evidence is early. We tell patients both halves of that.
- Nothing here is FDA approved. Exosome products are not approved for treatment of any condition in the United States.
What exosomes actually are
Every cell in your body releases them constantly, and until fairly recently we thought they were cellular rubbish. They turn out to be the postal service.
An exosome is a tiny membrane-bound vesicle — roughly 30 to 150 nanometres across, small enough that thousands would fit inside a single cell. Cells package specific cargo into them and release them into the surrounding fluid, where they are taken up by other cells.
The cargo is what matters. Exosomes carry growth factors, signalling peptides, lipids and messenger RNA — instructions that change the behaviour of the receiving cell. This is a genuine communication system, and one we only properly recognised in the last two decades.
The therapeutic interest follows from a specific realisation. When mesenchymal stem cells produce a regenerative effect, they often do not engraft and become new tissue. They release exosomes, and those exosomes instruct the local cells to repair. The signal may be doing much of the work the cell was credited with.
Which raises an obvious question: if the message is what matters, can you deliver the message without the cell? That is exosome therapy.
How the signal reaches the cell
Exosomes versus stem cell therapy
The practical argument for exosomes is that you get the signal without the complications of administering living cells — no viability question, no engraftment uncertainty, and a product that is far easier to characterise and standardise. The argument against is simply that the human evidence base is younger.
Why sourcing decides everything here
This is the part of exosome therapy that genuinely determines whether you are receiving something useful, and it is where the field has the most serious problems.
Exosome products vary enormously between suppliers. Particle count, purity, the presence of actual cargo rather than empty vesicles, sterility, and whether the product contains what the label claims are all variables — and independent testing has found substantial discrepancies.
The FDA has issued warnings about unapproved exosome products, and there have been documented cases of patient harm from contaminated preparations. That is not an argument against the science. It is an argument for asking hard questions about the specific product going into you.
Which laboratory produced this, and can I see the certificate of analysis? What is the particle count and how was it verified? What sterility testing was performed on this lot? A clinic that cannot answer those immediately is a clinic to walk away from. We can, and we will show you the documentation before you decide anything.
What we will also tell you plainly: exosome products are not FDA approved for the treatment of any condition. Anyone implying otherwise is misrepresenting the position.
The ten reasons patients ask us about exosomes
Ranked by how coherent the mechanism is and how much human evidence exists. The honest picture varies considerably down this list.
Joint and Soft Tissue Injury
The most common request and where the mechanism is most direct. Cartilage and tendon heal poorly because they are poorly vascularised, and delivering repair signalling directly into the tissue addresses that specific problem. Early clinical work is encouraging.
What the evidence showsExosomes are extracellular vesicles 30 to 150 nanometres in diameter carrying proteins, lipids and regulatory RNA. Phinney and Pittenger reviewed their role as the mediators of mesenchymal cell therapeutic effect in Stem Cells.Post-Surgical Recovery
Where tissue has been cut and needs to rebuild, the signalling that drives angiogenesis and fibroblast activity is exactly what recovery requires. Timing relative to the procedure matters and requires surgical coordination.
What the evidence showsBecause exosomes are cell-free, they carry no risk of immune rejection or unwanted differentiation, and they are considerably more stable than living cells in handling and storage.Chronic Tendinopathy
Tendon problems that have not resolved in months are often stalled rather than damaged — the healing process started and stopped. Exosomes, particularly alongside shockwave, are aimed at restarting it.
What the evidence showsExosome cargo includes microRNAs that regulate gene expression in recipient cells, providing a mechanism for effects that persist beyond the presence of the vesicles themselves.Skin and Aesthetic Applications
One of the fastest-growing uses, typically delivered with microneedling so the vesicles reach the dermis. The mechanism — signalling fibroblasts to produce collagen — is the same one behind red light therapy, delivered differently.
What the evidence showsExosomes promote angiogenesis and modulate macrophage polarisation toward reparative phenotypes, the same mechanisms attributed to their parent mesenchymal cells.Hair Restoration
Delivered into the scalp, aiming to signal follicles toward the growth phase and improve local perfusion. Early results reported in small series; larger controlled work is what the field needs.
What the evidence showsTheir small size allows exosomes to distribute more readily through tissue than whole cells, which are largely trapped in the pulmonary capillary bed after intravenous administration.Post-Viral and Inflammatory Conditions
Exosomes derived from mesenchymal cells carry anti-inflammatory and immunomodulatory cargo, which is mechanistically relevant where a dysregulated immune response is the problem. Genuinely early.
What the evidence showsTopical and injectable exosome preparations in dermatology have reported improvements in skin texture, fine lines and post-procedure recovery, with the mechanism being fibroblast stimulation.Neurological and Cognitive Applications
Among the most interesting areas in the research and among the least established clinically. Exosomes can cross the blood-brain barrier, which is precisely what makes this interesting and what makes caution appropriate.
What the evidence showsExosomes derived from mesenchymal cells reduce inflammatory cytokine production in experimental models, providing a mechanistic basis for their use in inflammatory joint conditions.Autoimmune Support
The immunomodulatory properties are the basis of interest here. We would use this as an adjunct within a broader root-cause protocol rather than as a primary intervention, and alongside your specialist.
What the evidence showsHair follicle applications rest on exosome effects on dermal papilla cell signalling and the growth phase of the follicle cycle.Athletic Recovery
Popular among athletes, and the mechanism for soft tissue recovery is coherent. Controlled performance data is essentially absent, and we would rather say that than let enthusiasm fill the gap.
What the evidence showsExosome preparations vary substantially between suppliers in particle count, purity and characterisation, which is why certificate of analysis documentation matters more here than in most fields.General Longevity Use
The least evidenced use on this list and the one most heavily marketed. Systemic exosome infusion for general anti-ageing purposes is an interesting idea without the human outcome data to support the claims being made for it.
What the evidence showsCombining exosomes with hyperbaric oxygen or photobiomodulation addresses tissue oxygenation and mitochondrial output alongside the signalling delivered, targeting the same repair process by complementary routes.What people commonly experience with this therapy
When patients receive the proper guidance, here is what people commonly experience with it.
- The first week — typically little. This is not a therapy with an immediate effect, and patients who expect one are usually disappointed. Signalling initiates a biological process; the process takes time.
- Weeks 2–6 — the first changes. In joint and soft tissue applications this is where reduced pain and improved function usually begin. In aesthetic applications, skin texture starts to change as collagen turnover responds.
- Weeks 6–12 — the substantive window. Tissue remodelling occurs over months rather than weeks. This is where most of the reported benefit appears, and where we reassess whether a second treatment is warranted.
- Months 3–6 — durability. The question that matters most and the one the field is still answering. We track function objectively rather than relying on recall, because that is the only way to know whether it held.
If you are considering exosome therapy, the most important thing is that somebody tells you honestly what it can and cannot do, and shows you exactly what product they are using. Schedule a consultation and my team will do both, and tell you plainly if something else would serve you better. Care from people who will not stop until the root cause of every one of your health issues has been found and addressed.
We will show you the certificate of analysis, tell you where the evidence genuinely sits, and say so if something else would serve you better.
Common questions
What is the difference between exosomes and stem cells?
Stem cells are living cells. Exosomes are the tiny signalling vesicles that cells release to communicate, carrying growth factors, peptides and messenger RNA. A key realisation in the field is that much of what stem cell therapy achieves may come from the exosomes those cells release rather than the cells engrafting. Exosome therapy delivers the signal without the cell.
Is exosome therapy FDA approved?
No. Exosome products are not approved by the FDA for the treatment of any condition in the United States, and the agency has issued warnings about unapproved products and documented cases of harm from contaminated preparations. Any clinic implying approval is misrepresenting the position.
How do I know the exosome product is good quality?
Ask three questions: which laboratory produced it, what is the verified particle count, and what sterility testing was performed on that specific lot. Ask to see the certificate of analysis. Product quality varies enormously between suppliers and independent testing has found substantial discrepancies between labelled and actual content.
How long does exosome therapy take to work?
It is not an immediate therapy. Signalling initiates a biological process and that process takes time. In joint and soft tissue applications, changes typically begin at two to six weeks with the substantive window at six to twelve. Anyone promising an immediate result is describing something other than the mechanism.
Is exosome therapy available near Nashville?
Yes, at our clinic in Franklin, Tennessee, about twenty minutes south of downtown Nashville. We will show you the sourcing documentation, give you a clear account of where the evidence sits for your specific use, and tell you if a different therapy would serve you better.
- Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science. 2020;367(6478):eaau6977. PMC7717626
- Phinney DG, Pittenger MF. Concise review: MSC-derived exosomes for cell-free therapy. Stem Cells. 2017;35(4):851–858.
- US Food and Drug Administration. Public safety notification on exosome products. 2019.
- Zhang B, Tian X, Hao J, et al. Mesenchymal stem cell-derived extracellular vesicles in tissue regeneration. Cell Transplantation. 2020;29:1–13.
This article is educational and reflects the published literature as of August 2026. It is not a diagnosis or a treatment recommendation for any individual, and any decision about your care belongs in a conversation with a licensed practitioner who has seen your history and your labs.